Many patients with severe gastroparesis unfortunately do not achieve adequate relief from the previously outlined therapies. In such cases, consideration should be given to implantation of a ...

Vanda Pharmaceuticals (VNDA) issued a letter to FDA Commissioner highlighting what the company considers a faulty gastroparesis NDA review.

The symptoms include constant nausea and vomiting. → Common treatment options → Questions to ask your doctor Gastroparesis is said to be caused by damaged nerves of the stomach. Diagnosis includes ...

Vanda Pharmaceuticals (NASDAQ:VNDA) has sent a letter to FDA Commissioner Robert Califf asserting that the review of the New ...

Diabetes mellitus is a risk factor for the development of gastroparesis. Currently, metoclopramide is the only US FDA-approved medication for the treatment of gastroparesis. However, the FDA ...

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) letter to FDA Commissioner highlights faulty gastroparesis NDA review.

Current research into effective treatments for gastroparesis is focused on agonists of motilin, a peptide hormone that accelerates gastric emptying. McCallum and colleagues studied whether ...

GIMOTI® (metoclopramide) nasal spray remains the sole FDA-approved treatment for diabetic gastroparesis, providing effective symptom relief and substantial cost savings compared to oral ...

After Vanda Pharmaceuticals’ phase 3 miss and FDA rejection for its stomach disorder candidate, CEO Mihael Polymeropoulos, ...

FDA posts update as mechanism to obtain unapproved Domperidone expected to lose supply in early 2025. Gimoti remains only approved drug shown to reduce hospitalizations, emergency ...

Evoke Pharma (EVOK) underscores its commitment to patients and healthcare providers managing gastroparesis in light of FDA’s recent update ...

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) letter to FDA Commissioner highlights faulty gastroparesis NDA review. As ...